Literature DB >> 27535563

Factors affecting biomarkers of endothelial and alveolar epithelial dysfunction.

Michihito Kyo1, Shinichiro Ohshimo2, Nobuaki Shime1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27535563     DOI： 10.1007/s00134-016-4460-y

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  5 in total

1.  Soluble RAGE and the RAGE ligands HMGB1 and S100A12 in critical illness: impact of glycemic control with insulin and relation with clinical outcome.

Authors:  Catherine Ingels; Inge Derese; Pieter J Wouters; Greet Van den Berghe; Ilse Vanhorebeek
Journal:  Shock       Date:  2015-02       Impact factor: 3.454

2.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis.

Authors:  P C Maisonpierre; C Suri; P F Jones; S Bartunkova; S J Wiegand; C Radziejewski; D Compton; J McClain; T H Aldrich; N Papadopoulos; T J Daly; S Davis; T N Sato; G D Yancopoulos
Journal:  Science       Date:  1997-07-04       Impact factor: 47.728

3.  Circulating markers of endothelial and alveolar epithelial dysfunction are associated with mortality in pediatric acute respiratory distress syndrome.

Authors:  Nadir Yehya; Neal J Thomas; Nuala J Meyer; Jason D Christie; Robert A Berg; Susan S Margulies
Journal:  Intensive Care Med       Date:  2016-04-21       Impact factor: 17.440

Review 4.  The biology of the receptor for advanced glycation end products and its ligands.

Authors:  A M Schmidt; S D Yan; S F Yan; D M Stern
Journal:  Biochim Biophys Acta       Date:  2000-12-20

Review 5.  Extracellular role of HMGB1 in inflammation and sepsis.

Authors:  H Wang; H Yang; K J Tracey
Journal:  J Intern Med       Date:  2004-03       Impact factor: 8.989
  5 in total
  1 in total

1.  Factors affecting biomarkers of endothelial and alveolar epithelial dysfunction: response to comments by Kyo et al.

Authors:  Nadir Yehya; Neal J Thomas; Nuala J Meyer; Susan S Margulies
Journal:  Intensive Care Med       Date:  2016-08-17       Impact factor: 17.440
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.